203 related articles for article (PubMed ID: 38241371)
21. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Colunga A; Pulliam T; Nghiem P
Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
[TBL] [Abstract][Full Text] [Related]
22. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
Baker M; Cordes L; Brownell I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
[TBL] [Abstract][Full Text] [Related]
23. Chronic mTOR activation promotes cell survival in Merkel cell carcinoma.
Lin Z; McDermott A; Shao L; Kannan A; Morgan M; Stack BC; Moreno M; Davis DA; Cornelius LA; Gao L
Cancer Lett; 2014 Mar; 344(2):272-281. PubMed ID: 24262658
[TBL] [Abstract][Full Text] [Related]
24. Merkel Cell Carcinoma Therapeutic Update.
Cassler NM; Merrill D; Bichakjian CK; Brownell I
Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
[TBL] [Abstract][Full Text] [Related]
25. Current and preclinical treatment options for Merkel cell carcinoma.
Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
Topalian SL; Bhatia S; Amin A; Kudchadkar RR; Sharfman WH; Lebbé C; Delord JP; Dunn LA; Shinohara MM; Kulikauskas R; Chung CH; Martens UM; Ferris RL; Stein JE; Engle EL; Devriese LA; Lao CD; Gu J; Li B; Chen T; Barrows A; Horvath A; Taube JM; Nghiem P
J Clin Oncol; 2020 Aug; 38(22):2476-2487. PubMed ID: 32324435
[TBL] [Abstract][Full Text] [Related]
27. Merkel Cell Carcinoma and Immune Evasion: Merkel Cell Polyomavirus Small T-Antigen‒Induced Surface Changes Can Be Reverted by Therapeutic Intervention.
Schlemeyer T; Ohnezeit D; Virdi S; Körner C; Weißelberg S; Starzonek S; Schumacher U; Grundhoff A; Indenbirken D; Albertini S; Fischer N
J Invest Dermatol; 2022 Nov; 142(11):3071-3081.e13. PubMed ID: 35636504
[TBL] [Abstract][Full Text] [Related]
28. Synergistic targeting of the PI3K/mTOR and MAPK/ERK pathways in Merkel cell carcinoma.
Temblador A; Topalis D; Andrei G; Snoeck R
Tumour Virus Res; 2022 Dec; 14():200244. PubMed ID: 36007768
[TBL] [Abstract][Full Text] [Related]
29. Association of Merkel Cell Polyomavirus Status With p53, RB1, and PD-L1 Expression and Patient Prognosis in Merkel Cell Carcinomas: Clinical, Morphologic, and Immunohistochemical Evaluation of 17 Cases.
Öğüt B; Bayram EK; İnan MA; Kestel S; Erdem Ö
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):371-378. PubMed ID: 37126387
[TBL] [Abstract][Full Text] [Related]
30. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
[TBL] [Abstract][Full Text] [Related]
31. Diffuse lichen planus-like keratoses and clinical pseudo-progression associated with avelumab treatment for Merkel cell carcinoma, a case report.
Cardis MA; Jiang H; Strauss J; Gulley JL; Brownell I
BMC Cancer; 2019 Jun; 19(1):539. PubMed ID: 31164102
[TBL] [Abstract][Full Text] [Related]
32. PD-1 blockade: a therapeutic option for treatment of metastatic Merkel cell carcinoma.
Winkler JK; Bender C; Kratochwil C; Enk A; Hassel JC
Br J Dermatol; 2017 Jan; 176(1):216-219. PubMed ID: 27038231
[TBL] [Abstract][Full Text] [Related]
33. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
34. Insights into anti-tumor immunity
Jani S; Church CD; Nghiem P
Front Immunol; 2023; 14():1172913. PubMed ID: 37287968
[TBL] [Abstract][Full Text] [Related]
35. The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression.
Srinivas N; Song L; Lei KC; Gravemeyer J; Furtmann F; Gambichler T; Becker JC; Sriram A
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8267-8277. PubMed ID: 37071208
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts.
Fang B; Kannan A; Zhao S; Nguyen QH; Ejadi S; Yamamoto M; Camilo Barreto J; Zhao H; Gao L
Sci Rep; 2020 Jun; 10(1):8867. PubMed ID: 32483262
[TBL] [Abstract][Full Text] [Related]
38. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
[TBL] [Abstract][Full Text] [Related]
40. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]